BEACON PHARMACEUTICALS PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 189.9 BDT | -2.96% |
|
-5.57% | -22.49% |
| Sales 2022 | 8.02B 72.95M 5.84B | Sales 2023 | 8.51B 77.38M 6.19B | Capitalization | 56.6B 515M 41.19B |
|---|---|---|---|---|---|
| Net income 2022 | 935M 8.5M 681M | Net income 2023 | 510M 4.64M 371M | EV / Sales 2022 | 7.85 x |
| Net Debt 2022 | 3.28B 29.85M 2.39B | Net Debt 2023 | 6.98B 63.45M 5.08B | EV / Sales 2023 | 7.47 x |
| P/E ratio 2022 |
63.8
x | P/E ratio 2023 |
111
x | Employees | 3,872 |
| Yield 2022 |
0.62% | Yield 2023 |
0.65% | Free-Float | 36.94% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.96% | ||
| 1 week | -5.57% | ||
| Current month | -7.55% | ||
| 1 month | -7.09% | ||
| 3 months | -15.52% | ||
| 6 months | -22.49% | ||
| Current year | -22.49% |
1 week
189.90
205.40
1 month
189.90224.00
Current year
189.90288.90
1 year
189.90288.90
3 years
112.50393.00
5 years
18.50393.00
10 years
11.20393.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 11/09/01 | |
| Director of Finance/CFO | - | - | |
| Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 11/09/01 | |
| Chairman | 64 | - | |
| Director/Board Member | 39 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/04/24 | 189.9 | -2.96% | 254,381 |
| 24/04/24 | 195.7 | +0.72% | 234,926 |
| 23/04/24 | 194.3 | -4.29% | 241,348 |
| 22/04/24 | 203 | +3.62% | 1,575,843 |
| 21/04/24 | 195.9 | -2.59% | 148,711 |
End-of-day quote Dhaka S.E., April 24, 2024
More quotes
Beacon Pharmaceuticals PLC, formerly Beacon Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract manufacturing and tool manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral and biotech. Its products include Favipiravir, Remdisivir INN, Meropenem, Bendamustine, Bleomycin Sulfate, Daunorubicin, Gemcitabine, Darbepoetin alfa and Filgrastim.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -22.49% | 400M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- BEACONPHAR Stock
